title: Preliminary report of the use on adults of a recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan.
abstract: Three 10 micrograms of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in an adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immunogenicity (anti-HBs titers between 17.5-29500 IU/ l, seroconversion 95.3%) and reactogenicity (no incapacitating side effects).
authors.affiliation: Serviço Especial de Saúde de Araraquara, São Paulo, Brasil.
authors.forename: A A
authors.initials: AA
authors.lastname: Costa
authors.forename: M
authors.initials: M
authors.lastname: Inenami
authors.forename: E
authors.initials: E
authors.lastname: Juarez
authors.forename: P D
authors.initials: PD
authors.lastname: Llacen
authors.forename: I
authors.initials: I
authors.lastname: Raw
mesh_terms: D000328:Adult; D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines; D006801:Humans; D008875:Middle Aged; D014614:Vaccines, Synthetic; D015003:Yeasts
chemical_list: D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic